However, the hERG1-mAb cannot be applied for in vivo cancer imaging, due to its large dimension and long half-life [20], which could impair tumor penetration and, conversely, facilitate the binding to the heart, i.e. the tissue where hERG1 is physiologically expressed. The gene discussed is KCNH2; the disease is cancer.